After a high dose of psilocybin, the brain desynchronizes at a massive scale, causing loss of our sense of self, time, and space. This may drive the burst of plasticity caused by psychedelics. The next day, brain activity has largely returned to normal, but an echo remains – a reset of circuits critical to the sense of self.
Our study is out today in @Nature https://t.co/PjACA6nkAy
This week @maps_pbc announced the submission of a NDA to the @US_FDA for MDMA assisted therapy for PTSD!
Part 1 of our series discussing the potential patient experience for MDMA. While there, sign up for the newsletter and get part 2 now!
#FDA#MDMA
https://t.co/jZn0WTPpYF
We’re pleased to announce that results from the investigator-initiated open-label study of investigational psilocybin treatment in bipolar II depression have been published in JAMA Psychiatry. The study was led by Dr Scott Aaronson at Sheppard Pratt and funded by Compass. You can read more in the full press release:
https://t.co/PozOYWVIs1
Opioid use disorder is a major focus in healthcare. We dive into the facts about OUD and explore utilizing psychedelics like ibogaine, LSD and ketamine as a potential solution.
#opioid#OUD#psychedelics#healthcare
https://t.co/apaz4A4ehz
"8 out of 10 patients were no longer depressed at 6 weeks after two doses of CYB003 12mg"
— Cybin Chief Medical Officer @dramirinamdar at the R&D Briefing on topline data from our Phase 2 study of CYB003 in MDD.
Watch the full briefing: https://t.co/AigH19BKNg 📺
Interested in getting quick, easy to read weekly content delivered to your inbox on the latest, scientific developments of psychedelics? Check out our website to find more articles written by our medical and business experts!
#psychedelics#medicine
https://t.co/F2eiPuv9pr
Ever wanted to sharpen your knowledge of the differences in language legislative bodies use when discussing access to psychedelics? Our most recent article provides an excellent breakdown of all the jargon!
#psychedelics#LegalizeIt#access
https://t.co/mAXklVJUPw
Recently we reviewed a study observing the potential of ibogaine and 5-MeO-DMT in transforming the lives of special operations veterans struggling with PTSD and alcohol use.
https://t.co/7gRJLNqpmI
#PTSD#Veterans#Ibogaine#research
We have been nominated for the Third Annual Wonderland Awards as part of the #WonderlandConference! Voting is available now until Fri, Nov 3rd. We are thankful for everyone that follows our content and would love your votes!!
#psychedelics
https://t.co/l1PiXyS1ou
This week learn about a pioneer in the field of psychedelic wellness @JoelBrierre! Joel is the cofounder of FIVE and founder and CEO of Kaivalya Kollectiv and Tandava Retreats. Follow to learn more on his work with 5-MeO-DMT!
#psychedelics#CEOSpotlight
https://t.co/pHP4fHC0WO
💥Continuing with our discussion last week on MDMA, we break down a recent study from @NatureMedicine on phase III trials of MDMA-assisted therapy in moderate to severe PTSD!
#psychedelics#PTSD#clinicaltrials
https://t.co/ohn0MME6Nq
Over the weekend, Gavin Newsom vetoed SB 58, which would have decriminalized psilocybin, DMT, and mescaline in California. 🫠
My most ~newsy~ story for WIRED yet: https://t.co/VsONsX7dpV
Unveiling the Remarkable Journey of MDMA Therapy!🧠
From blood loss prevention to a recreational sensation, MDMA has traversed a profound path. Now, it's on the verge of FDA approval, poised to transform PTSD treatment!
#MDMA#PTSDTherapy#psychedelics
https://t.co/7OFj5NjODC
@Psyched_Alpha@HLTHEVENT Article was coming from HLTH and plenty of projections out there discussing strong future performance in the psychedelic drug market. Your original post though, so did remove tweet
🌐✨ Delve deeper into the fascinating world of psychedelic innovation! After uncovering COMP360 groundbreaking strides, journey back in time to discover @CybinInc captivating work in the realm of psychedelic pharmaceuticals. 🚀 #Psychedelics#Innovation
https://t.co/Lq0P2Rk817
The Psychedelic Pulse is now live on X. Let our experts (MDs, PharmDs, PhDs, MBA, etc) be your weekly dose of science-backed psychedelic news. Check out our link in the bio to sign up and follow along! #psychedelics
🍄✨ Exciting News! @COMPASSPathways is pioneering mental health care with COMP360, their groundbreaking psilocybin formulation. Discover how this innovation could reshape the future of mental health. #Psychedelics#MentalHealthMatters
https://t.co/DRgDZnn5AW